Insulet (PODD) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue reached $488.5M, up 23.2% year-over-year, surpassing guidance due to strong Omnipod 5 demand, platform expansion, and international launches.

• Net income was $188.6M ($2.59 per diluted share), boosted by a $146.9M non-cash tax benefit from releasing a valuation allowance; adjusted net income was $38.3M ($0.55 per share).

• Omnipod 5 saw multiple successful launches and integrations in the U.S. and Europe, fueling growth and market leadership.

• Strategic decision to discontinue Omnipod GO resulted in a $13.5M inventory charge.

• New manufacturing facility in Malaysia began producing sellable product, supporting global expansion and expected margin improvement.

Financial highlights

• Total Omnipod revenue grew 26.3% to $480.4M; U.S. Omnipod up 27.3% to $352.3M, International up 23.5% to $128.1M.

• Gross margin improved to 67.7% (up 90 bps YoY), despite a $13.5M charge that reduced margin by 280 bps; would have been ~70.5% excluding the charge.

• Operating margin was 11.2% (up 340 bps YoY); adjusted EBITDA was $90.8M (18.6% of revenue), both above expectations.

• Cash and cash equivalents increased to $821.0M as of June 30, 2024; $300M available under credit facility.

• Released majority of valuation allowance, resulting in a non-cash tax benefit of ~$150M (adjusted out for non-GAAP purposes).

Outlook and guidance

• Full-year 2024 revenue growth guidance raised to 16%-19%, with Omnipod growth of 18%-21%; Q3 2024 revenue growth projected at 18%-21%.

• U.S. and International Omnipod revenue expected to grow 21%-24% year-over-year in Q3 2024.

• Gross margin for 2024 now expected near the high end of 68%-69% range, even with Omnipod GO charge; operating margin guidance raised to ~14%.

• Drug Delivery revenue expected to decline 40%-50% for the year, projected at $14–18M.

• R&D and SG&A expenses expected to rise in 2024 to support innovation and international expansion.